Exelixis | EXEL - Selling And Administration Expenses

Stock Price
44.24
Daily Change
0.61 1.40%
Monthly
1.44%
Yearly
19.15%
Q1 Forecast
42.28

Exelixis reported $123.02M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 124.9M 1.24M Sep/2025
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
Akebia Therapeutics USD 25.74M 1.93M Mar/2025
Amgen USD 1.94B 237M Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Bayer EUR 3.4B 140M Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Cytokinetics USD 158.75M 93.03M Sep/2025
Eisai JPY 111.72B 7.86B Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Esperion Therapeutics USD 39.98M 4.21M Sep/2024
Exelixis USD 123.02M 19.9M Dec/2025
Genmab DKK 144M 18M Jun/2025
Glaxosmithkline GBP 2.91B 817.89M Sep/2025
Incyte USD 390.41M 61.33M Dec/2025
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
MacroGenics USD 9.9M 600K Sep/2025
Merck USD 2.85B 215M Dec/2025
Moderna USD 308M 40M Dec/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Novartis USD 3.31B 134M Sep/2025
Pfizer USD 4.08B 894M Dec/2025
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Sanofi EUR 2.75B 455M Dec/2025
Takeda JPY 282.78B 29.23B Dec/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Xencor USD 87.78M 72.66M Sep/2025